ScholarLens Back to search
2005•Chinese New Drugs JournalRequires access

Efficacy and safety of mirtazapine for the treatment of generalized anxiety disorder

Wang Xin-you

Open publisher page 0 citations

Abstract

Objective: To evaluate the efficacy and safety of mirtazapine versus maprotiline in the treatment of generalized anxiety disorder (GAD). Methods: Of 60 patients with generalize anxiety disorder, 53 were randomly assigned to receive either mirtazapine (15～30mg·d~(-1), n=26) or maprotiline (50～150mg·d, n=27) for 6 weeks. The efficacy and safety of the study drugs were assessed with HAMD and TESS before the treatment and in weeks 1,2,4 and 6 after the treatment. Results: The overall response of mirtazapine and maprotiline was 84.69% and 66.67%, respectively, which showed no significant difference in Ridit analysis (P0.05). The incidence of adverse events in the mirtazapine group was fewer than in the maprotiline group (P0.05). Conclusion: Mirtazapine offers an alternative in the treatment of GAD.

About this research paper

What this paper is about

Objective: To evaluate the efficacy and safety of mirtazapine versus maprotiline in the treatment of generalized anxiety disorder (GAD). Methods: Of 60 patients with generalize anxiety disorder, 53 were randomly assigned to receive either mirtazapine (15～30mg·d~(-1), n=26) or maprotiline (50～150mg·d, n=27) for 6 weeks. The efficacy and safety of the study drugs were assessed with HAMD and TESS before the treatment and in weeks 1,2,4 and 6 after the treatment. Results: The overall response of mirtazapine and maprotiline was 84.69% and 66.67%, respectively, which showed no significant difference in Ridit analysis (P0.05). The incidence of adverse events in the mirtazapine group was fewer than in the maprotiline group (P0.05). Conclusion: Mirtazapine offers an alternative in the treatment of GAD.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective: To evaluate the efficacy and safety of mirtazapine versus maprotiline in the treatment of generalized anxiety disorder (GAD). Methods: Of 60 patients with generalize anxiety disorder, 53 were randomly assigned to receive either mirtazapine (15～30mg·d~(-1), n=26) or maprotiline (50～150mg·d, n=27) for 6 weeks. The efficacy and safety of the study drugs were assessed with HAMD and TESS before the treatment and in weeks 1,2,4 and 6 after the treatment. Results: The overall response of mirtazapine and maprotiline was 84.69% and 66.67%, respectively, which showed no significant difference in Ridit analysis (P0.05). The incidence of adverse events in the mirtazapine group was fewer than in the maprotiline group (P0.05). Conclusion: Mirtazapine offers an alternative in the treatment of GAD.

Key concepts: Mirtazapine, Maprotiline, Hamd, Generalized anxiety disorder, Anxiety, Medicine, Incidence (geometry), Adverse effect

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Efficacy and safety of mirtazapine for the treatment of generalized anxiety disorder — Research Paper | ScholarLens